Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 9, 2010

View Archived Issues

Aphios receives phase I of fast track SBIR grant for new nanodrug for AD

FDA advisory committee votes on sNDA for Avodart in prostate cancer

New GABA(A) alpha5 receptor ligands discovered at Roche

Phase I/II data presented on MLN-8237 in hematological malignancies

BI-6727 shows promise in phase I/II trial in acute myeloid leukemia

Bivalent oral poliovirus vaccine bOPV is superior to trivalent vaccine in Indian newborns

ACT Biotech describes unique mechanism of action of ACTB-1003

ArQule begins phase I trial of ARQ-736 in advanced solid tumors

LFB Biotechnologies completes acquisition of GTC Biotherapeutics

Gruenenthal presents new TRPV1 channel ligands

First European approval granted for Sumavel DosePro for migraine

Merck & Co. describes new somatostatin sst5 receptor antagonists

Sangart and U.S. navy join to develop MP4 to treat traumatic brain injury

Pharmaxis commences phase II trial of ASM-8 in asthma

Argos Therapeutics advances phase Ia trial of AGS-009 in SLE

Lilly divulges new vinyl indazolyl agents with antitumor activity

Medivation completes enrollment in phase III trial of Dimebon in Alzheimer's disease

New inhibitors of MAPK 14 identified by Merck & Co.

ArQule evaluates ARQ-087 in models of cancer

Neuraltus reports phase II data for NP-002 in levodopa-induced dyskinesias

RG-16781 improves negative symptoms of schizophrenia

Biogen and Swedish Orphan Biovitrum begin phase II/III rFVIIIFc trial

Expansion of phase IIa study of GeoVax's HIV/AIDS vaccine

PAION presents preclinical data on Solulin in hemophilia

Theratechnologies and sanofi-aventis enter agreement for Egrifta

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
Deals and an M&A strengthen end-of-year numbers
BioWorld
Two large deals and an acquisition, totaling about $4.64 billion in all, are helping wrap up what’s turning out to be a strong year. Through the first 11 months...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
Radiopharm Theranostics’ RAD-101 meets brain metastases endpoints
BioWorld
Radiopharm Theranostics Ltd.’s radiotracer RAD-101 met the primary endpoint in 92% of patients in the phase IIb imaging trial in brain metastases, according to...